GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - VAXCYTE INC

Explicit Guidance:

• BLA Submission (VAX31 Adult): Targeting a Biologics License Application (BLA) submission in the first half of 2028.
• Clinical Data Readouts (VAX31 Adult): Expectation to receive data from Opus 2 (concomitant with flu) and Opus 3 (revaccination) studies in the first half of next year.
• Infant Program Data (VAX31): Expecting Phase 2 data readout by the end of the first half of next year; data unblinding strategy leans toward concurrent disclosure of primary series and booster datasets.
• Manufacturing Consistency Study: Initiation of the manufacturing consistency study scheduled for 2027 to be completed prior to the 2028 BLA submission.
• VaxA1 (Group A Strep) Adult Phase 1: Moving to Stage 2 of Phase 1; expecting safety and tolerability data from the second half of next year to inform a Phase 2 study in school-aged children.
• Balance Sheet: Pro forma cash position of approximately $3.4 billion as of the end of September following a $1 billion financing.

Business-Segment Outlook:

• VAX31 Adult Market: The global pneumococcal market is projected to grow from $8.5B to ~$12B over the next several years, driven primarily by adult segment growth (currently $2.5–$3B) while the infant segment remains relatively flat.
• Market Share Shifts: Anticipated shift in adult-to-pediatric market ratio from ~33/67 to 50/50 over time due to adult market expansion.
• Competitive Landscape (PCV20/PCV21): Identifies a market gap created by competitors (PCV20/PCV21) missing key serotypes (specifically serotype 4 and 19F) which are rebounding in the US; aims to capture providers seeking a single vaccine covering both legacy and contemporary circulating serotypes.
• VAX31 Infant Program: Expected to cover 95% of invasive disease; aims to add 11 serotypes relative to PCV20, potentially improving otitis media outcomes.
• VaxA1 (Group A Strep): Targeting a $6B+ US market (direct medical costs only); aiming to demonstrate efficacy in a "reasonably sized" Phase 2 school-aged children study due to high attack rates.

Market and Competitive Outlook:

• FDA Thresholds: Notes FDA is applying more stringent immunogenicity thresholds (moving from 0.5 to ~0.667 or higher) to address "immunologic creep" observed in prior vaccines (7 to 21 valent); expects VAX31 to exceed these hurdles.
• Commercial Strategy: Planning to expand beyond current indications to include revaccination of patients with lesser valent vaccines and potential booster doses for high-risk groups (50+ age).
• International Growth: Expectation for ex-US adult programs to grow and align with US recommendations as national budgets expand, moving from restricted age groups (65+) to broader cohorts (50+).
• Pricing/Volume: Adult market volume driven by demographics and recommendation expansion; pediatric volume expected to remain constant with potential for price movement.

Macro / Industry Outlook:

• Market Dynamics: Projected structural growth in adult pneumococcal disease burden and vaccination rates.
• Regulatory Environment: Anticipates continued FDA scrutiny on immunogenicity breadth versus carrier suppression, favoring vaccines that maintain high immunogenicity across 30+ serotypes.
• Disease Trends: Cites increasing invasive Group A Strep disease in adults and high antibiotic usage for GBS in youth as drivers for the VaxA1 pipeline.

Strategic Initiatives:

• Manufacturing Capacity: Currently building inventory and conducting process development to support a commercial launch of VAX31 adult.
• Pipeline Expansion: Advancing VaxA1 from Phase 1 Stage 2 adults to planned Phase 2 in school-aged children; leveraging platform technology for multiple adult and pediatric opportunities.
• Capital Allocation: Utilizing $3.4B cash on hand to fully fund expected VAX31 adult launch and advance all pipeline programs.
• Dose Optimization: Modified infant VAX31 study design to include higher dose arms (up to 4.4 micrograms) based on observed dose-dependent immune response in prior 24-valent studies.

Risks and Headwinds to Outlook:

• Clinical/Regulatory: Risk that infant Phase 2 data (point estimates) may show variance in lower-response serotypes, though management believes an "approvable profile" will be achieved; potential for FDA to require additional non-inferiority thresholds.
• Manufacturing: Complexity of demonstrating consistency for 31 serotypes across 3 ECRIMs and 3 DPs; timing dependent on completing the 2027 manufacturing consistency study.
• Competitive: Continued market uptake of PCV21 and potential for other competitors to launch broader coverage vaccines if VAX31 faces delays.
• Execution: Dependence on successful unblinding and disclosure strategy (concurrent vs. sequential) for infant data.

Management Tone on the Future:

• Confidence Level: High; data exceeded expectations ("thrilled," "robust"), and the team expresses "high anticipation" for upcoming infant data.
• Strategic Clarity: Clear pivot to a 50/50 adult-pediatric revenue model; strong belief that VAX31 solves the "trade-off" problem for providers regarding serotype coverage.
• Hedges: Explicitly noted that the 2028 BLA timeline reflects the "substantial volume of work" required rather than commercial un readiness; infant data focus is on "point estimates" due to study size limitations.
• Differentiation: Emphasizes that "breadth of coverage" is the primary commercial driver and that VAX31 is uniquely positioned to capture this demand.